Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Corona Remedies Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹1,062
Per ShareLot Size
14 Shares
Minimum Investment
₹14,868
Issue Size
₹655.37 Cr
Face Value
₹10
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
72.5%
Promoter Holding (Post-Issue)
69%
Issue Type
Book Building
ISIN
INE02ZQ01018
We are an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Our diversified product portfolio comprises 71 brands catering to a range of therapeutic areas such as women's healthcare, cardio-diabeto, pain management and urology, among others, as of June 30, 2025. Of our targeted therapeutic areas, our women's healthcare segment contributed to 28.56% (or Rs.4,080.26 million), cardiodiabeto (comprising cardio-vascular and anti-diabetic areas) contributed 23.38% (or Rs.3,339.96 million), pain management contributed 11.79% (or Rs.1,684.38 million) and urology contributed 4.53% (or Rs.646.65 million) to our domestic sales for MAT June 2025.
As of Financial Year 2025, the Indian domestic formulation market, holding a market size of approximately Rs.2.3 trillion, accounted for approximately 2% of the overall global pharmaceutical market. India possesses an ecosystem to develop and manufacture pharmaceuticals, with companies having state-of-the-art facilities and skilled technical manpower. The domestic market (consumption) logged a healthy CAGR of 9% between Financial Years 2020 and 2025. It is expected to clock a CAGR of 8-9% to reach Rs.3.3-3.5 trillion by Financial Year 2030, aided by strong demand on account of rising incidences of chronic diseases, awareness and access to quality healthcare.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of 6,174,051 equity shares of face value of Rs.10/- each ("equity shares") of Corona Remedies Limited ("company") for cash at a price of Rs.1,062/- per equity share ("offer price") aggregating to Rs.655.37 crores ("offer"), comprising an offer for sale of 1,223,193 equity shares of face value of Rs.10/- each aggregating to Rs.129.84 crores by Kirtikumar Laxmidas Mehta ("promoter selling sharheolder"), 721,691 equity shares of face value of Rs.10/- each aggregating to Rs.76.61 crores by Minaxi Kirtikumar Mehta, 97,853 equity shares of face value of Rs.10/- each aggregating to Rs.10.39 crores by Dipabahen Niravkumar Mehta, 97,853 equity shares of face value of Rs.10/- each aggregating to Rs.10.39 crores by Brinda Ankur Mehta ("promoter group selling shareholders"), 3,811,613 equity shares of face value of Rs.10/- each aggregating to Rs.404.60 crores by Sepia Investments Limited, 142,488 equity shares of face value of Rs.10/- each aggregating to Rs.15.13 crores by Anchor Partners and 79,360 equity shares of face value of Rs.10/- each aggregating to Rs.8.42 crores by Sage Investment Trust ("investor selling shareholders", and along with the promoter selling shareholder and promoter group selling shareholders, the "selling shareholders") ("offer for sale", and such equity shares offered in the offer for sale, the "offered shares").
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Our Company was originally incorporated as `CORONA Remedies Private Limited', a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on October 24, 2024, and consequently, the name of our Company was changed to `CORONA Remedies Limited'. A fresh certificate of incorporation, upon conversion of our Company to a public limited company was issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.
Wholesaler and Retailer
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.